• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ASAHI KASEI MEDICAL CO., LTD. PLASMAFLO OP; PLASMA SEPARATOR,

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ASAHI KASEI MEDICAL CO., LTD. PLASMAFLO OP; PLASMA SEPARATOR, Back to Search Results
Model Number OP-08D
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problem Urticaria (2278)
Event Date 03/20/2023
Event Type  Injury  
Manufacturer Narrative
The product of this event was not returned to the manufacturer and could not be analyzed.There is no information on physician's opinion regarding seriousness and causal relationship between this event and the use of the medical device.We consider urticaria as "serious injury" since it was a systemic urticaria and steroids are being administered via iv as a treatment, and the causal relationship between the urticaria and the use of the medical device cannot be denied.Urticaria is described as one of the adverse events in "e.Precautions" of ifu.We will continue to monitor the occurrence of similar events carefully.
 
Event Description
This incident occurred in japan.Plasmaflo op-d series is identical model to op-05w(a) marketed in us.Patient with chronic inflammatory demyelinating polyradiculoneuropathy received simple plasma exchange treatments using op-08d.Albumin was used as replacement fluid.Five minutes after the 5th treatment on (b)(6) 2023, urticaria developed throughout the body and treatment was discontinued.Drug allergy was suspected, and loxoprofen sodium hydrate and nafamostat mesilate were discontinued.After discontinuing treatment, steroid was administered via iv, but it was discontinued due to severe drowsiness.About 15 minutes after the start of the 6th treatment on (b)(6) 2023, urticaria also appeared all over the body, but the treatment was continued.At the time of this treatment, no drug was used.Patient's symptom was improved after completion of treatment.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
PLASMAFLO OP
Type of Device
PLASMA SEPARATOR,
Manufacturer (Section D)
ASAHI KASEI MEDICAL CO., LTD.
1-1-2 yurakucho
chiyoda-ku
tokyo, 100-0 006
JA  100-0006
Manufacturer (Section G)
ASAHI KASEI MEDICAL MT CORP.
2111-2 oaza sato
oita-shi
oita, 870-0 396
JA   870-0396
Manufacturer Contact
naomi kagami
1-1-2 yurakucho
chiyoda-ku
tokyo, 100-0-006
JA   100-0006
MDR Report Key16721660
MDR Text Key313140347
Report Number8010002-2023-00020
Device Sequence Number1
Product Code MDP
Combination Product (y/n)N
Reporter Country CodeJA
PMA/PMN Number
P820033
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Foreign,Health Professional
Reporter Occupation Other Health Care Professional
Type of Report Initial
Report Date 03/23/2023
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received04/12/2023
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Model NumberOP-08D
Device Lot NumberN/A
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Date Manufacturer Received03/23/2023
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Patient Sequence Number1
Patient Outcome(s) Other;
-
-